← All Avidity Biosciences, INC filings

Avidity Biosciences, INC Form 4 insider transactions

NASDAQ
RNA
Avidity Biosciences, INC
Form 4: Avidity Biosciences CEO Sarah Boyce Executes Stock Option and Sells Shares
Avidity Biosciences' CEO, Sarah Boyce, exercised stock options and sold shares on April 2, 2024, according to a recent SEC filing.
NASDAQ
RNA
Avidity Biosciences, INC
Form 4: Avidity Biosciences Director Levin Exercises Options and Sells Shares
Director Arthur A. Levin exercised stock options and sold shares of Avidity Biosciences (RNA) on March 19, 2024.
NASDAQ
RNA
Avidity Biosciences, INC
Form 4: Avidity Biosciences CFO Michael MacLean Exercises Options and Sells Shares
Michael MacLean, CFO of Avidity Biosciences, exercised stock options and sold 40,000 shares of common stock on March 13, 2024.
NASDAQ
RNA
Avidity Biosciences, INC
Form 4: Avidity Biosciences Director Arthur Levin Exercises Options and Sells Shares
Director Arthur Levin exercised stock options and sold shares of Avidity Biosciences on March 12, 2024.
NASDAQ
RNA
Avidity Biosciences, INC
Form 4: Avidity Biosciences CEO Sarah Boyce Executes Stock Options and Sells Shares
Avidity Biosciences' CEO, Sarah Boyce, exercised stock options and sold shares of common stock in multiple transactions on March 8 and March 12, 2024.
NASDAQ
RNA
Avidity Biosciences, INC
Form 4: Avidity Biosciences CEO Exercises and Sells Shares Under 10b5-1 Plan
Avidity Biosciences CEO Sarah Boyce executed stock options and sold shares on March 1, 2024, under a pre-arranged 10b5-1 trading plan.